Aravive, Inc. is a Houston-based clinical-stage biopharmaceutical company focused on developing novel therapeutics for life-threatening diseases, with a primary emphasis on oncology. Its lead candidate, AVB-500, targets critical pathways involved in cancer progression and metastasis, underscoring the firm's innovative proprietary technology platform. As Aravive progresses through clinical trials, it aims to meet pressing unmet medical needs in cancer therapy, positioning itself as a compelling investment opportunity for institutional investors interested in the forefront of biopharmaceutical advancements. Show more

Location: RIVER OAKS TOWER, HOUSTON, TX, UNITED STATES, 77098, 3730 Kirby Drive, Suite 1200, Texas, 77098, USA | Website: https://aravive.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

2.95M

52 Wk Range

$0.00 - $0.00

Previous Close

$0.04

Open

$0.04

Volume

N/A

Day Range

$0.04 - $0.04

Enterprise Value

0.00

Cash

8.535M

Avg Qtr Burn

-9.808M

Insider Ownership

38.69%

Institutional Own.

8.21%

Qtr Updated

09/30/23

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Batiraxcept (AVB-500) Details Renal cell carcinoma	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Batiraxcept (AVB-500) Details Pancreatic cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Batiraxcept (AVB-500) Details Solid tumor/s, Cancer, Renal cell carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Batiraxcept (AVB-500) Details Solid tumor/s, Cancer, Ovarian cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.